Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers

Inclusion Criteria: 1. Healthy subjects between the ages of 18 and 45 years; 2. Body weight no less than 50 kg for male, no less than 45 kg for female; Body Mass Index of 19 to 26kg/m2; 3. Physical examination, vital signs examination, laboratory examination, ECG, B-ultrasound and fundus examination results were normal or abnormal without clinical significant; 4. Subjects who are willing to take proper contraceptive during the study and within 3 months after the study completed; 5. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the informed consent form; Exclusion Criteria: 1. Subjects with hypersensitivity to VV116 or any of the excipients; 2. Subjects with allergic diseases or allergic constitution; 3. Subjects with central nervous system,cardiovascular system,gastrointestinal, respiratory system,urinary,Hematologic System,metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; 4. Blood donation or blood loss ≥ 400 mL within 3 months prior to inclusion, or have a history of blood product use history; 5. Participated in a clinical study involving another investigational drug within 3 month before the screening visit; 6. Taken any prescription drugs, non-prescription drugs, Chinese herbal medicine or health care products within 2 weeks prior to screening; 7. Drug or alcohol addicts within 1 year prior to screening, who drink at least twice a day or more than 14 units per week, or who are addicted to alcohol (1 unit ≈200 mL beer with 5% alcohol content, 25 mL spirits with 40% alcohol content or 85 mL wine with 12% alcohol content) ; 8. Those who smoke more than 10 cigarettes per day and do not agree to avoid using any tobacco products during the trial period; 9. Those who cannot quit smoking or drinking during the trial; 10. Those who are positive for hepatitis B surface antigen (HBsAg), HCV antibody, syphilis antibody and HIV antibody; 11. Abnormal and clinically significant chest radiographs (anteroposterior); 12. B ultrasound examination showed moderate to severe fatty liver; 13. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeded the upper normal limit (ULN) at screening time or baseline; 14. Glomerular filtration rate (eGFR) \< 90 mL/min/1.73m2 at screening time or baseline; 15. Abnormal ecg at screening or baseline, single QTcF (corrected for heart rate) \> 450 ms in men, \> 470 ms in women, and/or other clinically significant abnormalities; 16. Pregnant or lactating women or male subjects whose spouse has a child care plan within 3 months; 17. The investigator believes that there are other factors that are not suitable for participating in this trial.